Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ALMS
vs
S&P 500
ALMS
S&P 500
Over the past 12 months, ALMS has significantly outperformed S&P 500, delivering a return of +54% compared to S&P 500's +16% growth.
Stocks Performance
ALMS vs S&P 500
Performance Gap
ALMS vs S&P 500
Performance By Year
ALMS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Alumis Inc
Glance View
Alumis Inc. is a biotechnology company focused on developing medicines for immune-related diseases, especially conditions where the body’s immune system attacks healthy tissue. Its work centers on creating small-molecule drugs that can be taken by mouth and are designed to control inflammation more precisely than older treatments. The company does not sell a broad consumer product line. Instead, it advances drug candidates through research and clinical testing, then looks to earn money through future drug sales, partnerships, licensing deals, or other commercialization arrangements if those medicines are approved. Its main customers, in the long run, would be doctors, hospitals, and patients treating autoimmune and inflammatory diseases. What makes Alumis different is its role early in the drug-development chain. It is not a drug distributor or generic manufacturer; it is an R&D-driven company trying to turn laboratory science into approved treatments. That means its business depends on finding drug candidates that can move through clinical trials and, if successful, can be licensed, partnered, or sold in the market as prescription medicines.